Shares of AtriCure Inc. (NASDAQ:ATRC) have received an average recommendation of “Hold” from the eleven ratings firms that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and six have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $24.33.

ATRC has been the subject of several analyst reports. Canaccord Genuity reduced their price objective on shares of AtriCure from $28.00 to $24.00 and set a “buy” rating for the company in a research note on Thursday, November 2nd. Needham & Company LLC reduced their price objective on shares of AtriCure from $26.00 to $25.00 and set a “buy” rating for the company in a research note on Thursday, November 2nd. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $24.00 price objective on shares of AtriCure in a research note on Sunday, December 10th. TheStreet lowered shares of AtriCure from a “c-” rating to a “d+” rating in a research note on Wednesday, November 29th. Finally, Zacks Investment Research raised shares of AtriCure from a “sell” rating to a “hold” rating in a research note on Monday, October 2nd.

Shares of AtriCure (NASDAQ ATRC) opened at $17.73 on Tuesday. The stock has a market cap of $611.23, a price-to-earnings ratio of -17.38 and a beta of 0.66. AtriCure has a 52 week low of $14.78 and a 52 week high of $25.18. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.65 and a current ratio of 2.28.

AtriCure (NASDAQ:ATRC) last issued its earnings results on Wednesday, November 1st. The medical device company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.02. The company had revenue of $42.20 million during the quarter, compared to analyst estimates of $43.44 million. AtriCure had a negative net margin of 17.19% and a negative return on equity of 18.14%. The company’s revenue for the quarter was up 10.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.21) EPS. equities research analysts expect that AtriCure will post -0.96 earnings per share for the current fiscal year.

In related news, CFO M. Andrew Wade sold 2,000 shares of AtriCure stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $18.41, for a total value of $36,820.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director B Kristine Johnson bought 1,500 shares of the company’s stock in a transaction that occurred on Wednesday, November 8th. The stock was purchased at an average price of $18.36 per share, for a total transaction of $27,540.00. Following the acquisition, the director now directly owns 10,969 shares in the company, valued at $201,390.84. The disclosure for this purchase can be found here. Company insiders own 11.90% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in ATRC. Campbell & CO Investment Adviser LLC bought a new position in AtriCure in the 3rd quarter worth $205,000. Legal & General Group Plc raised its holdings in AtriCure by 3.8% in the 2nd quarter. Legal & General Group Plc now owns 8,528 shares of the medical device company’s stock worth $208,000 after acquiring an additional 312 shares during the period. Tudor Investment Corp ET AL bought a new position in AtriCure in the 2nd quarter worth $253,000. UBS Asset Management Americas Inc. bought a new position in AtriCure in the 2nd quarter worth $315,000. Finally, Voya Investment Management LLC raised its holdings in AtriCure by 7.9% in the 2nd quarter. Voya Investment Management LLC now owns 17,158 shares of the medical device company’s stock worth $416,000 after acquiring an additional 1,250 shares during the period. Hedge funds and other institutional investors own 86.17% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was first posted by American Banking News and is the property of of American Banking News. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/01/16/atricure-inc-atrc-receives-consensus-rating-of-hold-from-brokerages.html.

AtriCure Company Profile

AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.

Analyst Recommendations for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.